CASE REPORT
Huge splenomegaly, a rare presentation
of multicentric Castleman’s disease
in an HIV-infected patient: a case report
and literature review
1
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Department of Infectious Diseases, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
2
Department of Radiology, Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences, Tehran, Iran
3
Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
4
Department of Pathology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
Submission date: 2022-04-23
Final revision date: 2022-06-16
Acceptance date: 2022-06-22
Publication date: 2024-10-14
Corresponding author
Ladan Abbasian
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
HIV & AIDS Review 2024;23(3):268-272
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Castleman’s disease (CD) is characterized by non-neoplastic lymph node hyperplasia, and may be localized in a single lymph node (unicentric) or occurs systemically (multicentric). Nowadays, multicentric CD is most commonly observed in individuals infected with human immunodeficiency virus (HIV) type 1, in association with Kaposi’s sarcoma. Histopathologic and immunohistochemical evaluation of excised lymph node as well as imaging modalities, such as computed tomography (CT) and magnetic resonance imaging, are required for the diagnosis of CD.
Case description:
We present a case of 46-year-old HIV-infected woman with fever, weakness, weight loss, and splenomegaly in the past 18 months. On physical examination, pale conjunctiva, jaundice, multiple cervical, inguinal, and axillary lymphadenopathies as well as hepatosplenomegaly were detected. Chest CT scan showed alveolar opacity in the lower lobe of the right lung and multiple lymph nodes in the mediastinum and bilateral perivascular, cervical, and axillary areas. Abdominopelvic CT scan showed huge splenomegaly, hepatomegaly, and multiple bilateral para-aortic, celiac, and inguinal lymphadenopathies, which were further confirmed as CD in pathological examination.
Conclusions:
Huge splenomegaly is a rare manifestation in CD. Among the more prevalent differential diagnoses, CD in patients with HIV and huge splenomegaly was emphasized as important differential diagnosis.
Castleman’s disease (CD) is characterized by non-neoplastic lymph node hyperplasia, and may be localized in a single lymph node (unicentric) or occurs systemically (multicentric). Nowadays, multicentric CD is most commonly observed in individuals infected with human immunodeficiency virus (HIV) type 1, in association with Kaposi’s sarcoma. Histopathologic and immunohistochemical evaluation of excised lymph node as well as imaging modalities, such as computed tomography (CT) and magnetic resonance imaging, are required for the diagnosis of CD.
Case description:
We present a case of 46-year-old HIV-infected woman with fever, weakness, weight loss, and splenomegaly in the past 18 months. On physical examination, pale conjunctiva, jaundice, multiple cervical, inguinal, and axillary lymphadenopathies as well as hepatosplenomegaly were detected. Chest CT scan showed alveolar opacity in the lower lobe of the right lung and multiple lymph nodes in the mediastinum and bilateral perivascular, cervical, and axillary areas. Abdominopelvic CT scan showed huge splenomegaly, hepatomegaly, and multiple bilateral para-aortic, celiac, and inguinal lymphadenopathies, which were further confirmed as CD in pathological examination.
Conclusions:
Huge splenomegaly is a rare manifestation in CD. Among the more prevalent differential diagnoses, CD in patients with HIV and huge splenomegaly was emphasized as important differential diagnosis.
REFERENCES (21)
1.
Oksenhendler E, Duarte M, Soulier J, Cacoub P, Welker Y, Cadranel J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10: 61-67.
2.
Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 1995; 86: 1276-1280.
3.
Cronin DM, Warnke RA. Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol 2009; 16: 236-246.
4.
Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph‐node hyperplasia resembling thymoma. Cancer 1956; 9: 822-830.
5.
Powles T, Stebbing J, Bazeos A, Hatzimichael E, Mandalia S, Nelson M, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol 2009; 20: 775-779.
6.
Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129: 3-17.
7.
Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009; 4: 16-21.
8.
Bower M, Powles T, Williams S, Davis TN, Atkins M, Montoto S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007; 147: 836-839.
9.
Du M, Bacon C, Isaacson P. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol 2007; 60: 1350-1357.
10.
Dupin N, Diss TL, Kellam P, Tulliez M, Du MQ, Sicard D, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95: 1406-1412.
11.
Yabuhara A, Yanagisawa M, Murata T, Kawai H, Komiyama A, Akabane T, et al. Giant lymph node hyperplasia (castleman’s disease) with spontaneous production of high levels of b‐cell differentiation factor activity. Cancer 1989; 63: 260-265.
12.
Leger-Ravet M, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, et al. Interleukin-6 gene expression in Castleman’s disease. Blood 1991; 78: 2923-2930.
13.
Murakami M, Kamimura D, Hirano T. Pleiotropy and specificity: insights from the interleukin 6 family of cytokines. Immunity 2019; 50: 812-831.
14.
Zhao S, Wan Y, Huang Z, Song B, Yu J. Imaging and clinical features of Castleman disease. Cancer Imaging 2019; 19: 1-8.
15.
Hill A, Tirumani S, Rosenthal M, Shinagare A, Carrasco R, Munshi N, et al. Multimodality imaging and clinical features in Castleman disease: single institute experience in 30 patients. Br J Radiol 2015; 88: 20140670. DOI: 10.1259/bjr.20140670.
16.
Meador TL, McLarney JK. CT features of Castleman disease of the abdomen and pelvis. Am J Roentgenol 2000; 175: 115-118.
17.
Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10: 25-35.
18.
Ricciardi L, Furci F, Ieni A, Macrì A. Castleman disease in a patient with common variable immunodeficiency. Case Rep Immunol 2019; 2019: 5476383. DOI: 10.1155/2019/5476383.
19.
Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, et al. Durable remission with rituximab in a patient with an unusual variant of Castleman’s disease with myelofibrosis – TAFRO syndrome. Am J Hematol 2015; 90: 1091-1092.
20.
Suneja S, Chidambaram M, Herzenberg AM, Bargman JM. Kidney involvement in multicentric castleman disease. Am J Kidney Dis 2009; 53: 550-554.
21.
Pinto AL, Gomes M, Cipriano MA, Ribeiro ML. Non-cirrhotic portal hypertension associated with multicentric Castleman’s disease: a case report. Acta Oncol 2018; 57: 703-705.
| eISSN: | 1732-2707 |
| ISSN: | 1730-1270 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
